Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
20 July 2015

ORYZON Genomics to present at the 2015 Alzheimer's Association International Conference

12 November 2010

Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics

1 March 2011

Oryzon to Present Recent Advances from its Project 'Innovative Approaches and Biomarkers in Parkinson Disease' at a Symposium in Barcelona

17 May 2011

Oryzon presents the results of the clinical study of GynEC-Dx: detection of endometrial cancer product

8 June 2011

Oryzon is present in the 76th Spanish National Congress of Urology

27 June 2011

Oryzon is present at the Bio International Convention of USA

6 July 2011

Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine

7 July 2011

Oryzon on the official program of the Euromediag International Convention (EIC 2011)

13 September 2011

ORYZON, PALO BIOPHARMA AND AROMICS awarded with funding for JOINT research program

15 September 2011

Oryzon will launch its first product onto the market

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Current page 51
  • Page 52
  • Page 53
  • Page 54
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel